Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > MTNB Matinas BioPharma > Detailed Quotes

MTNB Matinas BioPharma

0.643
+0.014+2.23%
Close 09/26 16:00 ET
0.670
+0.027+4.18%
Post Mkt Price 09/26 16:59 ET
High
0.649
Open
0.610
Turnover
141.45K
Low
0.603
Pre Close
0.629
Volume
226.51K
Market Cap
139.47M
P/E(TTM)
Loss
52wk High
1.260
Shares
216.86M
P/E(Static)
Loss
52wk Low
0.490
Float Cap
133.77M
Bid/Ask %
98.33%
Historical High
3.950
Shs Float
208.01M
Volume Ratio
0.78
Historical Low
0.310
Dividend TTM
--
Div Yield TTM
--
P/B
3.25
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.11%
Amplitude
7.33%
Avg Price
0.624
Lot Size
1
Float Cap
133.77M
Bid/Ask %
98.33%
Historical High
3.950
Shs Float
208.01M
Volume Ratio
0.78
Historical Low
0.310
Dividend TTM
--
P/B
3.25
Dividend LFY
--
Turnover Ratio
0.11%
Amplitude
7.33%
Avg Price
0.624
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling the delivery of life-changing medicines using its LNC platform technology. The firm's proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins, and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. Its anti-fungal product candidate, MAT2203, delivers a broad-spectrum fungicidal agent, amphotericin B, and is being developed to prevent invasive fungal infections in patients with acute lymphoblastic leukemia. The company was founded by Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.
CEO: --
Market: AMEX
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...